Geburtshilfe und Frauenheilkunde, Table of Contents Geburtshilfe Frauenheilkd 2003; 63(4): R65-R92DOI: 10.1055/s-2004-817986 GebFra-Refresher Georg Thieme Verlag Stuttgart · New York Update primäres Mammakarzinom 2003 M. W. Beckmann1 , P. A. Fasching1 , J. M. Weiss2 , A. Magener1 , O. Ortmann2 1Erlangen 2Lübeck Recommend Article Abstract Buy Article Full Text References Literatur 1 von Minckwitz G, Brunnert K, Costa S D. et al . Primärbehandlung von Mammakarzinomen. Frauenarzt. 2002; 43 920-931 2 Goldhirsch A, Glick J H, Gelber R D. et al . Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001; 19 3817-3827 3 NHS Cancer Screening programmes .Breast Screening (UK) Annual Review; www.cancerscreening.nhs.uk. 2003 4 Beckmann M W, Nestle-Kraemling C, Lux M P. et al . Das Familiäre Mammakarzinom-Syndrom: prädiktive genetische Testung, Beratung und Betreuung. Med Welt. 2001; 12 385-390 5 Boyd N F, Lockwood G A, Martin L J. et al . Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst. 1999; 91 1404-1408 6 Schmutzler R K, Beckmann M W, Kiechle M. Prävention: Familiäres Mamma- und Ovarialkarzinom. Deutsches Ärzteblatt. 2002; 99 20:A1372/B1146/C1071 7 de Jong M M, Nolte I M, te Meerman G J. et al . Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet. 2002; 39 225-242 8 Oppelt P G, Beckmann M W. Risikofaktoren und -beurteilung in der Menopause. Geburtsh Frauenheilk. 2001; 61 257-267 9 Beckmann M W, Schulz-Wendtland R. Mammadiagnostik Teil 1. Geburtsh Frauenheilk. 2001; 61 R1-R15 10 Fasching P A, Aichinger U, Schulz-Wendtland R. et al . Mammadiagnostik Teil 2. Geburtsh Frauenheilk. 2002; 62 R17-R32 11 Smith R A, Cokkinides V, Eyre H J. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003; 53 27-43 12 Nystrom L, Andersson I, Bjurstam N. et al . Long-term effects of mammography screening: Updated overview of the Swedish randomised trials. Lancet. 2002; 359 909-919 13 Horton R. Screening mammography - an overview revisited. Lancet. 2001; 358 1284-1285 14 Baselga J. A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell. 2002; 2 93-95 15 Piccart M, Lohrisch C, Di Leo A. et al . The predictive value of HER2 in breast cancer. Oncology. 2001; 61 (Suppl 2) 73-82 16 Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer. 2001; 8 191-195 17 Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol. 2000; 27 46-52 18 Osborne C K, Bardou V, Hopp T A. et al . Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003; 95 353-361 19 Schiff R, Massarweh S, Shou J. et al . Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003; 9 447S-454S 20 Sobin L H, Wittekind C. TNM Classification of Malignant Tumours. 6 ed. New York:; John Wiley & Sons 2002: 239 21 Galimberti V, Veronesi P, Arnone P. et al . Stage migration after biopsy of internal mammary chain lymph nodes in breast cancer patients. Ann Surg Oncol. 2002; 9 924-928 22 Silverstein M J. In: Silverstein MJ (ed). Ductal Carcinoma in Situ of the Breast. Vol. 2. New York; Lippincott Williams & Wilkins 2002: 682 23 Fisher B, Land S, Mamounas E. et al . Prevention of invasive breast cancer in women with ductal Carcinoma in situ: an Update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001; 28 400-418 24 Pichert G, Bolliger B, Buser K. et al . Evidence-based management options for women at increased breast/ovarian cancer risk. Ann Oncol. 2003; 14 9-19 25 EBCTCG . Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351 1451-1467 26 Cuzick J, Powles T, Veronesi U. et al . Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003; 361 296-300 27 Jonat W, Kaufmann M, Sauerbrei W. et al . Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002; 20 4628-4635 28 The Trialists' A TAC. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359 2131-2139 29 Blanchard D K, Hartmann L C. Prophylactic surgery for women at high risk for breast cancer. Clin Breast Cancer. 2000; 1 127-134 30 Meijers-Heijboer H, van Geel B, van Putten W L. et al . Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345 159-164 31 Rebbeck T R, Lynch H T, Neuhausen S L. et al . Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002; 346 1616-1622 32 Rebbeck T R. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2000; 18 100S-103S 33 Kauff N D, Satagopan J M, Robson M E. et al . Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346 1609-1615 34 Brekelmans C T, Seynaeve C, Bartels C C. et al . Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001; 19 924-930 35 van ‘t Veer L J, Dai H, van de Vijver M J. et al . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415 530-536 36 van de Vijver M J, He Y D, van't Veer L J. et al . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347 1999-2009 37 Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer. 1999; 35 1963-1973 38 Galimberti V, Zurrida S, Intra M. et al . Sentinel node biopsy interpretation: The Milan Experience. Breast J. 2000; 6 306-309 39 Bonnema J, Van De Velde C J. Sentinel lymph node biopsy in breast cancer. Ann Oncol. 2002; 13 1531-1537 40 Fisher B, Bryant J, Wolmark N. et al . Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16 2672-2685 41 Gerber B, Krause A, Friese K. Rekonstruktive und plastisch ästhetische Mammaoperationen. Deutsches Ärzteblatt. 2003; 8 A474/B411/C388 42 Overgaard J, Bartelink H. Breast cancer survival advantage with radiotherapy. Lancet. 2000; 356 1269-1270 43 Early Breast Cancer Trialists' Collaborative Group . Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351 1451-1467 44 Winer E P, Hudis C, Burstein H J. et al . American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002; 20 3317-3327 45 Love R R, Duc N B, Allred D C. et al . Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol. 2002; 20 2559-2566 46 Pritchard K I, Levine M N, Bramwell V HC. et al .A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: Update of NCIC CTG MA. 5. San Antonio Breast Cancer Symposium. 2002: S17 47 Thor A D, Berry D A, Budman D R. et al . erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998; 90 1346-1360 48 Paik S, Bryant J, Park C. et al . erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998; 90 1361-1370 49 Fisher E R, Wang J, Bryant J. et al . Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002; 95 681-695 50 Albain K S. Adjuvnant chemo-endocrine therapy in breast cancer: Combined or sequential. Breast. 2003; 12 (Suppl 1) S36
